Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860

A bivalent chromatin structure marks key developmental genes in embryonic stem cells

Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.041 · Cited by 5,361

Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing

Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775

Detection of large-scale variation in the human genome

Iafrate, A. J., Feuk, L., Rivera, M. N., Listewnik, M. L., Donahoe, P. K., Qi, Y., Scherer, S. W., & Lee, C. (2004) · Nature Genetics · doi:10.1038/ng1416 · Cited by 2,892

The Polycomb group protein EZH2 directly controls DNA methylation

Viré, E., Brenner, C., Deplus, R., Blanchon, L., Fraga, M., Didelot, C., Morey, L., Van Eynde, A., Bernard, D., Vanderwinden, J.-M., et al. (2006) · Nature · doi:10.1038/nature04431 · Cited by 2,204

Mutation in TET2 in Myeloid Cancers

Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin

Morin, R. D., Johnson, N. A., Severson, T., Mungall, A. J. J., An, J., Goya, R., Paul, J. E., Boyle, M., Woolcock, B. W., Kuchenbauer, F. C., et al. (2010) · Nature Genetics · doi:10.1038/ng.518 · Cited by 1,719

Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein

Kuzmichev, A., Nishioka, K., Erdjument-Bromage, H., Tempst, P., & Reinberg, D. (2002) · Genes & Development · doi:10.1101/gad.1035902 · Cited by 1,596

Histone Methyltransferase Activity of a Drosophila Polycomb Group Repressor Complex

Müller, J., Hart, C. M., Francis, N. J., Vargas, M. L., Sengupta, A. K., Wild, B., Miller, E., O’Connor, M. B., Kingston, R. E., & Simon, J. A. (2002) · Cell · doi:10.1016/s0092-8674(02)00976-5 · Cited by 1,553

Drosophila Enhancer of Zeste/ESC Complexes Have a Histone H3 Methyltransferase Activity that Marks Chromosomal Polycomb Sites

Czermin, B., Melfi, R., McCabe, D., Seitz, V., Imhof, A., & Pirrotta, V. (2002) · Cell · doi:10.1016/s0092-8674(02)00975-3 · Cited by 1,536

Memory of Divisional History Directs the Continuous Process of Primitive Hematopoietic Lineage Commitment

Bernitz, J. M., Rapp, K., Daniel, M. G., Shcherbinin, D., Yuan, Y., Gomes, A., Waghray, A., Brosh, R., Lachmann, A., Ma’ayan, A., et al. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.03.005 · Cited by 17

Differentiation Therapy

Chen, S., Yan, X., Zhou, G., & Chen, Z. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm011 · Cited by 15

Emerging drugs for polycythemia vera

Tibes, R., & Mesa, R. A. (2013) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2013.832754 · Cited by 14

Tumor-suppressive functions of protein lysine methyltransferases

Aziz, N., Hong, Y. H., Kim, H. G., Kim, J. H., & Cho, J. Y. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01117-7 · Cited by 14

Acquired Uniparental Disomy in Myeloproliferative Neoplasms

Score, J., & Cross, N. C. P. (2012) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2012.07.002 · Cited by 14

An epigenetic view of B‐cell disorders

Alberghini, F., Petrocelli, V., Rahmat, M., & Casola, S. S. (2015) · Immunology and Cell Biology · doi:10.1038/icb.2014.116 · Cited by 15

Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium

Tefferi, A., Abdel-Wahab, O. I., Cervantes, F., Crispino, J. D., Finazzi, G., Girodon, F., Gisslinger, H., Gotlib, J. R., Kiladjian, J., Levine, R. L., et al. (2011) · Blood Cancer Journal · doi:10.1038/bcj.2011.4 · Cited by 16

Recent Progress in the Discovery of Small-Molecule Inhibitors of the Hmt Ezh2 for the Treatment of Cancer

Verma, S. K., & Knight, S. D. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.136 · Cited by 15

Lysine-specific histone demethylases in normal and malignant hematopoiesis

Andricovich, J., Yan, K., & Tzatsos, A. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.05.006 · Cited by 14

Management of myelofibrosis: JAK inhibition and beyond

Stahl, M. F., & Zeidan, A. M. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1317590 · Cited by 14

PRR14L mutations are associated with chromosome 22 acquired uniparental disomy, age-related clonal hematopoiesis and myeloid neoplasia

Chase, A., Pellagatti, A., Singh, S., Score, J., Tapper, W., Lin, F., Hoade, Y., Bryant, C., Trim, N., Yip, B. H., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0340-5 · Cited by 14

Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms

Sharma, V., Wright, K. L., Epling‐Burnette, P. K., & Reuther, G. W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.604142 · Cited by 16

CUX1 in leukemia: dosage matters

Boultwood, J. (2013) · Blood · doi:10.1182/blood-2012-12-473421 · Cited by 14

Molecular Genetic Biomarkers in Myeloid Malignancies

Matynia, A. P., Szankasi, P., Shen, W., & Kelley, T. W. (2014) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2014-0096-ra · Cited by 15

Genetic defects in PRC2 components other than EZH2 are not common in myeloid malignancies

Kroeze, L. I., Nikoloski, G., da Silva-Coelho, P., van Hoogen, P., Stevens-Linders, E., Kuiper, R. P., Schnittger, S., Haferlach, T., Pahl, H. L., van der Reijden, B. A., et al. (2012) · Blood · doi:10.1182/blood-2011-07-365213 · Cited by 14

Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure?

Nazha, A., Khoury, J. D., Verstovšek, S., & Daver, N. G. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.06.013 · Cited by 16

Another Piece of the Myeloproliferative Neoplasms Puzzle

Levine, R. L. (2013) · New England Journal of Medicine · doi:10.1056/nejme1313643 · Cited by 14

EZH2-mediated H3K27me3 is a predictive biomarker and therapeutic target in uveal melanoma

Hou, C., Xiao, L., Ren, X., Cheng, L., Guo, B., Zhang, M., & Yan, N. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1013475 · Cited by 13

Profound parental bias associated with chromosome 14 acquired uniparental disomy indicates targeting of an imprinted locus

Chase, A., Leung, W., Tapper, W., Jones, A. V., Knoops, L., Rasi, C., Forsberg, L. A., Guglielmelli, P., Zoi, K., Hall, V., et al. (2015) · Leukemia · doi:10.1038/leu.2015.130 · Cited by 13

Azacitidine Use for Myeloid Neoplasms

Fakih, R. O. E., Komrokji, R. S., Shaheen, M., Almohareb, F. I., Rasheed, W. K., & Hassanein, M. F. R. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.02.005 · Cited by 13

CBFβ-SMMHC Affects Genome-wide Polycomb Repressive Complex 1 Activity in Acute Myeloid Leukemia

Cordonnier, G., Mandoli, A., Cagnard, N., Hypolite, G., Lhermitte, L., Verhoeyen, E., Asnafi, V., Dillon, N., Macintyre, E. A., Martens, J. H. A., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2019.12.026 · Cited by 13

Evolving insights on histone methylome regulation in human acute myeloid leukemia pathogenesis and targeted therapy

Boila, L. D., & Sengupta, A. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.09.189 · Cited by 12

The Mutational Landscape of Myeloid Leukaemia in Down Syndrome

de Castro, C. P. M., Cadefau-Fabregat, M., & Cuartero, S. (2021) · Cancers · doi:10.3390/cancers13164144 · Cited by 16

Myelodysplastic Syndrome: Diagnosis and Screening

Tria, F., Ang, D. C., & Fan, G. (2022) · Diagnostics · doi:10.3390/diagnostics12071581 · Cited by 13

Role of Enhancer of Zeste Homolog 2 Polycomb Protein and Its Significance in Tumor Progression and Cell Differentiation

Marchesi, I., & Bagell, L. (2013) · InTech eBooks · doi:10.5772/55370 · Cited by 15

Submicroscopic deletion of 5q involving tumor suppressor genes (CTNNA1, HSPA9) and copy neutral loss of heterozygosity associated with TET2 and EZH2 mutations in a case of MDS with normal chromosome and FISH results

Hemmat, M., Chen, W., Anguiano, A. L., Naggar, M. E., Racke, F. K., Jones, D., Wang, Y., Strom, C. M., Chang, K., & Boyar, F. Z. (2014) · Molecular Cytogenetics · doi:10.1186/1755-8166-7-35 · Cited by 13

Immunophenotypic, cytogenetic, and mutational characterization of cell lines derived from myelodysplastic syndrome patients after progression to acute myeloid leukemia

Palau, A., Mallo, M., Palomo, L., Hernández‐Rodríguez, I., Diesch, J., Campos, D., Granada, I., Juncà, J., Drexler, H. G., Solé, F. G., et al. (2016) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22430 · Cited by 13

Polycomb repressive complex 2 haploinsufficiency identifies a high-risk subgroup of pediatric acute myeloid leukemia

Bond, J., Labis, E. B., Marceau‐Renaut, A., Duployez, N., Labopin, M., Hypolite, G., Michel, G., Ducassou, S., Boutroux, H., Nelken, B., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0187-9 · Cited by 13

Point Mutations in Myelodysplastic Syndromes

Damm, F., Fontenay, M., & Bernard, O. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1108665 · Cited by 14

Polycomb segment myeloid malignancies

Saunthararajah, Y., & Maciejewski, J. (2012) · Blood · doi:10.1182/blood-2011-12-391268 · Cited by 12

Targeting low-risk myelodysplastic syndrome with novel therapeutic strategies

Trivedi, G., Inoue, D., & Zhang, L. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.06.013 · Cited by 14

A specific form of cPRC1 containing CBX4 is co-opted to mediate oncogenic gene repression in diffuse midline glioma

Lagan, E., Gannon, D., Silva, A. J., Bibawi, P., Doherty, A. M., Nimmo, D., McCole, R., Monger, C., Genesi, G. L., Vanderlinden, A., et al. (2025) · Molecular Cell · doi:10.1016/j.molcel.2025.04.026 · Cited by 16

The epigenomics revolution in myelodysplasia: a clinico-pathological perspective

Tan, P. T., & Wei, A. H. (2011) · Pathology · doi:10.1097/pat.0b013e32834a4061 · Cited by 12

Induced pluripotent stem cell technology for dissecting the cancer epigenome

Semi, K., & Yamada, Y. (2015) · Cancer Science · doi:10.1111/cas.12758 · Cited by 12

Molecular basis and clonal evolution of myeloproliferative neoplasms

Jäger, R., & Královics, R. (2010) · Haematologica · doi:10.3324/haematol.2009.019570 · Cited by 12

CRISPR screening in human hematopoietic stem and progenitor cells reveals an enrichment for tumor suppressor genes within chromosome 7 commonly deleted regions

Baeten, J. T., Liu, W., Preddy, I., Zhou, N., & McNerney, M. E. (2022) · Leukemia · doi:10.1038/s41375-021-01491-z · Cited by 11

Genome-wide profiling reveals epigenetic inactivation of the PU.1 pathway by histone H3 lysine 27 trimethylation in cytogenetically normal myelodysplastic syndrome

Cheng, J. X., Anastasi, J., Watanabe, K. Q., Kleinbrink, E. L., Grimley, E. C., Knibbs, R., Shen, Q. J., & Vardiman, J. W. (2013) · Leukemia · doi:10.1038/leu.2013.45 · Cited by 12

Aberrant differential expression of EZH1 and EZH2 in Polycomb repressive complex 2 among B- and T/NK-cell neoplasms

Al-Kader, L. A., Oka, T., Takata, K., Sato, H., Murakami, I., Otte, A. P., & Yoshino, T. (2016) · Pathology · doi:10.1016/j.pathol.2016.05.002 · Cited by 12

Mutational mechanisms of EZH2 inactivation in myeloid neoplasms

Chase, A., Score, J., Lin, F., Bryant, C., Waghorn, K., Yapp, S., Carreño‐Tarragona, G., Aranaz, P., Villasante, A., Ernst, T., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0816-y · Cited by 13

Enhancing mitochondrial function in vivo rescues MDS-like anemia induced by pRb deficiency

Sen, T., Jain, M. V., Gram, M., Mattebo, A., Soneji, S., Walkley, C. R., & Singbrant, S. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.06.006 · Cited by 13

Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility

Hou, H., & Tien, H. (2016) · Expert Review of Hematology · doi:10.1586/17474086.2016.1144469 · Cited by 13

EZH2 orchestrates apicobasal polarity and neuroepithelial cell renewal

Akizu, N., & Martínez‐Balbás, M. A. (2016) · Neurogenesis · doi:10.1080/23262133.2016.1250034 · Cited by 12

Co-occurrence of a maternally inherited DNMT3A duplication and a paternally inherited pathogenic variant in EZH2 in a child with growth retardation and severe short stature: atypical Weaver syndrome or evidence of a DNMT3A dosage effect?Preprint

Polonis, K., Blackburn, P. R., Urrutia, R. A., Lomberk, G. A., Kruisselbrink, T., Cousin, M. A., Boczek, N. J., Hoppman, N. L., Babovic‐Vuksanovic, D., Klee, E. W., et al. (2018) · Molecular Case Studies · doi:10.1101/mcs.a002899 · Cited by 12

Tyrosine 1–phosphorylated RNA polymerase II transcribes PROMPTs to facilitate proximal promoter pausing and induce global transcriptional repression in response to DNA damagePreprint

Ajit, K., Alagia, A., Burger, K., & Gullerová, M. (2024) · Genome Research · doi:10.1101/gr.278644.123 · Cited by 12

Analyzing Genetic Differences Between Sporadic Primary and Secondary/Tertiary Hyperparathyroidism by Targeted Next-Generation Panel Sequencing

Hong, Y. A., Park, K. C., Kim, B. K., Lee, J., Sun, W. Y., Sul, H. J., Hwang, K.-A., Choi, W. J., Chang, Y., Kim, S. Y., et al. (2021) · Endocrine Pathology · doi:10.1007/s12022-021-09686-x · Cited by 11

Oncogenes and the Origins of Leukemias

Brown, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042293 · Cited by 15

The evolution of preclinical models for myelodysplastic neoplasms

Mina, A. A., Pavletic, S. Z., & Aplan, P. D. (2024) · Leukemia · doi:10.1038/s41375-024-02181-2 · Cited by 11

Polycomb repressive complex 2 (PRC2) pathway’s role in cancer cell plasticity and drug resistance

Goleij, P., Heidari, M. M., Tabari, M. A. K., Hadipour, M., Rezaee, A., Javan, A., Sanaye, P. M., Larsen, D. S., Daglia, M., & Khan, H. (2025) · Functional & Integrative Genomics · doi:10.1007/s10142-025-01563-8 · Cited by 13

Whole-exome sequencing enhances prognostic classification of myeloid malignancies

Ruffalo, M., Husseinzadeh, H. D., Makishima, H., Przychodzen, B. P., Ashkar, M., Koyutürk, M., Maciejewski, J. P., & LaFramboise, T. (2015) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2015.10.003 · Cited by 11

New Molecular Abnormalities and Clonal Architecture in AML: From Reciprocal Translocations to Whole-Genome Sequencing

Graubert, T. A., Brunner, A. M., & Fathi, A. T. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.e334 · Cited by 12

Insights into novel emerging epigenetic drugs in myeloid malignancies

Chandhok, N. S., & Prébet, T. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620719866081 · Cited by 11

Republished: Non-heritable genetics of human disease: spotlight on post-zygotic genetic variation acquired during lifetime

Forsberg, L. A., Absher, D., & Dumanski, J. P. (2013) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2012-101322rep · Cited by 12

Semi-Quantitative Mass Spectrometry in AML Cells Identifies New Non-Genomic Targets of the EZH2 Methyltransferase

Sbirkov, Y., Kwok, C., Bhamra, A., Thompson, A., Gil, V., Zelent, A., & Petrie, K. R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071440 · Cited by 11

Targeting epigenetics using synthetic lethality in precision medicine

Chen, E. S. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2866-0 · Cited by 11

The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia

Gonzalez‐Lugo, J. D., Chakraborty, S., Verma, A., & Shastri, A. (2020) · Seminars in Hematology · doi:10.1053/j.seminhematol.2020.12.003 · Cited by 11

Disease modifying agents of myeloproliferative neoplasms: a review

Lee, S. (2021) · Blood Research · doi:10.5045/br.2021.2020325 · Cited by 11

Molecular and clinical aspects relevant for counseling individuals with clonal hematopoiesis of indeterminate potential

Cacic, A. M., Schulz, F. I., Germing, U., Dietrich, S., & Gattermann, N. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1303785 · Cited by 12

Hematopoiesis during development, aging, and disease

Jung, J., Buisman, S. C., & de Haan, G. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.05.007 · Cited by 10

Revertant somatic mosaicism as a cause of cancer

Inaba, T., & Nagamachi, A. (2021) · Cancer Science · doi:10.1111/cas.14852 · Cited by 10

Differential requirement for the Polycomb repressor complex 2 in dendritic cell and tissue-resident myeloid cell homeostasis

Zhan, Y., Zhang, Y., Zhang, S., Coughlan, H. D., Baldoni, P. L., Jacquelot, N., Cao, W. H. J., Preston, S., Louis, C., Rautela, J., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abf7268 · Cited by 12

Investigational epigenetically targeted drugs in early phase trials for the treatment of haematological malignancies

Okosun, J., Packham, G., & Fitzgibbon, J. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.923402 · Cited by 12

Use of Single Nucleotide Polymorphism Array Technology to Improve the Identification of Chromosomal Lesions in Leukemia

Iacobucci, I., Lonetti, A., Papayannidis, C., & Martinelli, G. (2013) · Current Cancer Drug Targets · doi:10.2174/15680096113139990089 · Cited by 10

De novo childhood myelodysplastic/myeloproliferative disease with unique molecular characteristics

Ismael, O., Shimada, A., Hama, A., Elshazley, M., Muramatsu, H., Goto, A., Sakaguchi, H., Tanaka, M., Takahashi, Y., Xu, Y., et al. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09140.x · Cited by 10

Epigenomic Consequences of Coding and Noncoding Driver Mutations

Yao, X., Xing, M., Ooi, W. F., Tan, P. B. O., & Teh, B. T. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.09.002 · Cited by 10

Concomitant MDS with isolated 5q deletion and MGUS : case report and review of molecular aspects

Nolte, F., Mossner, M., Jann, J.-C., Nowak, D., Boch, T., Müller, N., Hofmann, W., & Metzgeroth, G. (2016) · European Journal Of Haematology · doi:10.1111/ejh.12827 · Cited by 10

Recurrent Subcutaneous Sweet's Disease in a Myelofibrosis Patient Treated with Ruxolitinib before Allogeneic Stem Cell Transplantation

Sakoda, T., Kanamitsu, Y., Mori, Y., Sasaki, K., Yonemitsu, E., Nagae, K., Yoshimoto, G., Kamezaki, K., Kato, K., Takenaka, K., et al. (2017) · Internal Medicine · doi:10.2169/internalmedicine.8491-16 · Cited by 10

Atypical Chronic Myeloid Leukemia, BCR/ABL1 Negative

Levinson, K. B., & Bagg, A. (2017) · Molecular pathology library · doi:10.1007/978-3-319-62146-3_11 · Cited by 10

A Structural Perspective on Gene Repression by Polycomb Repressive Complex 2

Liu, X. (2020) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-030-58971-4_17 · Cited by 11

Chromatin Regulator SPEN/SHARP in X Inactivation and Disease

Giaimo, B. D., Robert-Finestra, T., Oswald, F., Gribnau, J. H., & Borggrefe, T. (2021) · Cancers · doi:10.3390/cancers13071665 · Cited by 12

Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia

Fontana, D., Gambacorti-Passerini, C. B., & Piazza, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.756348 · Cited by 10

Polycomb contraction differentially regulates terminal human hematopoietic differentiation programs

Lorzadeh, A., Hammond, C. A., Wang, F., Knapp, D. J. H. F., Wong, J., Zhu, J., Cao, Q., Heravi‐Moussavi, A., Carles, A., Wong, M. M.-K., et al. (2022) · BMC Biology · doi:10.1186/s12915-022-01315-1 · Cited by 8

EZH2 Mutations: Mutating the Epigenetic Machinery in Myeloid Malignancies

Abdel-Wahab, O. I., & Levine, R. L. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.07.006 · Cited by 10

Tumor suppressor p53 protein expression: prognostic significance in patients with low-risk myelodysplastic syndrome

Duarte, F. B., Gonçalves, R. P., Barbosa, M. C., Filho, F. D. R., dos Santos, T. E. D. J., dos Santos, T. N., & de Vasconcelos, P. R. L. (2014) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.1016/j.bjhh.2014.03.007 · Cited by 10

The Role of Chromatin-Associated Proteins in Cancer

Helin, K., & Minucci, S. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-034422 · Cited by 9

Dominant-negative effects of Weaver syndrome-associated EZH2 variantsPreprint

Deevy, O., Li, J., Monger, C., Matrà, F., Tuck, E., Davies, M., Badonyi, M., Boyce, M., Doyle, E. J., Hokamp, K., et al. (2025) · Genes & Development · doi:10.1101/gad.351884.124 · Cited by 10

The NEXT complex regulates H3K27me3 levels to affect cancer progression by degrading G4/U-rich lncRNAs

Yang, Q., Zhou, Z., Li, L., Lu, R., Hou, G., Huang, C., Huang, J., Li, H., Zhang, Y., Li, J., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf107 · Cited by 9

Development of a High-Resolution Melting Analysis for the Detection of the SF3B1 Mutations

Yang, J. C., Qian, J., Lin, J., Yang, X., Qian, W., Chen, Q., Yao, D., Wang, C., Chen, X.-X., Xiao, G.-F., et al. (2013) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2012.0364 · Cited by 9

Molecular Pathogenesis of Chronic Myelomonocytic Leukemia and Potential Molecular Targets for Treatment Approaches

Geissler, K. H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.751668 · Cited by 8

Targeting the LSD1/KDM1 Family of Lysine Demethylases in Cancer and Other Human Diseases

Mao, F., & Shi, Y. G. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-38176-8_2 · Cited by 9

Noncoding rules of survival: epigenetic regulation of normal and malignant hematopoiesis

Wallace, L. M., & Obeng, E. A. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1273046 · Cited by 11

Histone Methylation in Chromatin Signaling

Gozani, O., & Shi, Y. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8624-4_5 · Cited by 8

Antitumorigenic effect of interferon-β by inhibition of undifferentiated glioblastoma cells

Yamamuro, S., Sano, E., Okamoto, Y., Ochiai, Y., OHTA, T., Ogino, A., Natsume, A., Wakabayashi, T., UEDA, T., Hara, H., et al. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3165 · Cited by 9

Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes

Savona, M. R., Sochacki, A. L., & Fischer, M. A. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s83868 · Cited by 9

Recent Progress in the Discovery of Epigenetic Inhibitors for the Treatment of Cancer

Verma, S. K. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-1804-1_35 · Cited by 9

Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) Overlap Syndromes: Molecular Pathogenetic Mechanisms and Their Implications

Pati, H., & Veetil, K. K. (2019) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-019-01084-y · Cited by 9

Epigenetic Control of Infant B Cell Precursor Acute Lymphoblastic Leukemia

de Barrios, O., & Parra, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063127 · Cited by 10

Lessons from mouse models of MPN

Benlabiod, C., Dagher, T., Marty, C., & Villeval, J. (2021) · International review of cytology · doi:10.1016/bs.ircmb.2021.02.009 · Cited by 13

EZH2 and Endometrial Cancer Development: Insights from a Mouse Model

Fang, X. D., Ni, N., Wang, X., Tian, Y., Ivanov, I. V., Rijnkels, M., Bayless, K. J., Lydon, J. P., & Li, Q. (2022) · Cells · doi:10.3390/cells11050909 · Cited by 9

New pieces of a puzzle: The current biological picture of MPN

Kleppe, M., & Levine, R. L. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.07.002 · Cited by 9

Molecular basis and clonal evolution of myeloproliferative neoplasms

Cleary, C., & Královics, R. (2013) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2013-0135 · Cited by 9

Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?

Nazha, A., & Gerds, A. T. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0380 · Cited by 9

A novel assay to detect calreticulin mutations in myeloproliferative neoplasms

Rosso, V., Petiti, J., Bracco, E., Pedrola, R., Carnuccio, F., Signorino, E., Carturan, S., Calabrese, C., Bot‐Sartor, G., Ronconi, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.14113 · Cited by 9

Panel sequencing of 264 candidate susceptibility genes and segregation analysis in a cohort of non-BRCA1, non-BRCA2 breast cancer families

kConFab Investigators, Li, J., Li, H., Makunin, I. V., Thompson, B. A., Tao, K., Young, E. L., Lopez, J., Camp, N. J., Tavtigian, S. V., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4469-0 · Cited by 9

Polycomb repressive complex 2 binds RNA irrespective of stereochemistry

Deckard, C. E., & Sczepanski, J. T. (2018) · Chemical Communications · doi:10.1039/c8cc07433j · Cited by 9

Pathobiology of Acute Myeloid Leukemia

Brunner, A. M., & Graubert, T. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00058-5 · Cited by 9

Transposable elements as novel therapeutic targets for PARPi-induced synthetic lethality in PcG-mutated blood cancer

Zeisig, B. B., Tsai, C., Virely, C., Fung, T. K., Akin, A. T., Troadec, E., Jiao, B., Thompson, I. R., Lau, P. N. I., Li, N., et al. (2025) · Blood · doi:10.1182/blood.2025028560 · Cited by 9

Role of Additional Novel Therapies in Myeloproliferative Neoplasms

Fiskus, W. C., Ganguly, S., Kambhampati, S., & Bhalla, K. N. (2012) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2012.07.001 · Cited by 8

Viewing AML through a New Lens: Technological Advances in the Study of Epigenetic Regulation

Godfrey, L., & Rodríguez-Meira, A. (2022) · Cancers · doi:10.3390/cancers14235989 · Cited by 7

Disordered Epigenetic Regulation in the Pathophysiology of Myeloproliferative Neoplasms

Zhang, S., & Abdel-Wahab, O. I. (2011) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-011-0105-y · Cited by 8

EZH2 Mutations: Mutating the Epigenetic Machinery in Myeloid Malignancies

Abdel-Wahab, O. I., & Levine, R. L. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.07.006 · Cited by 10

Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes

Nikoloski, G., Langemeijer, S. M. C., Kuiper, R. P., Knops, R., Massop, M., Tönnissen, E., van der Heijden, A., Scheele, T. N., Vandenberghe, P., de Witte, T., et al. (2010) · Nature Genetics · doi:10.1038/ng.620 · Cited by 777

Inactivating mutations of the histone methyltransferase EZH2 in myeloid disorders

Ernst, T., Chase, A., Score, J., Hidalgo-Curtis, C., Bryant, C., Jones, A. E., Waghorn, K., Zoi, K., Ross, F., Reiter, A., et al. (2010)

Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms

Score, J., Hidalgo-Curtis, C., Jones, A. V., Winkelmann, N., Skinner, A., Ward, D., Zoi, K., Ernst, T., Stegelmann, F., Döhner, K., et al. (2012) · Blood · doi:10.1182/blood-2011-07-367243 · Cited by 177

Mitotic recombination in haematological malignancy

Raghavan, M., Gupta, M., Molloy, G. Y., Chaplin, T., & Young, B. D. (2009) · Advances in Enzyme Regulation · doi:10.1016/j.advenzreg.2009.10.030 · Cited by 5